DOT1L and cancer: A further indication that this epigenetic regulator may represent a predictor of poor patient survival comes from the observation that DOT1L expression in mice is prompted by the stimulation of cancer cells with interleukin-22 (IL-22), predominantly produced by CD4+ T cells, resulting in enhanced CRC cell stemness (Kryczek et al., 2014).